Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end

Eli Lilly has jumped back into bed with ImmunoGen. Several years after terminating an earlier deal, Lilly has struck a new agreement, paying $13 million upfront and committing up to $1.7 billion in total to pick up rights to another antibody-drug conjugate (ADC) technology.